BioSenic Valuation

Is BT1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BT1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BT1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BT1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BT1?

Key metric: As BT1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BT1. This is calculated by dividing BT1's market cap by their current revenue.
What is BT1's PS Ratio?
PS Ratio	0.6x
Sales	€2.87m
Market Cap	€1.67m

BT1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.6x
Enterprise Value/EBITDA	-8.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BT1's PS Ratio compare to its peers?

The above table shows the PS ratio for BT1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.3x
ECX Epigenomics	8.4x	n/a	€1.1m
BPXA Bellicum Pharmaceuticals	0.5x	n/a	€772.4k
SBH Sangui Biotech International	3.8x	n/a	€419.8k
CNW co.don	0.7x	n/a	€6.5m
BT1 BioSenic	0.6x	n/a	€1.7m

Price-To-Sales vs Peers: BT1 is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (4x).

Price to Sales Ratio vs Industry

How does BT1's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.1x	21.8%
BT1 BioSenic	0.6x	n/a	US$1.74m
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	8.1x	42.4%
BT1 BioSenic	0.6x	n/a	US$1.74m

No more companies

Price-To-Sales vs Industry: BT1 is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is BT1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BT1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BT1's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.90

3.6%

75.1%

Perrigo

US$3.8b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$27.00

6.8%

-3.6%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

3.6%

22.9%